Levetiracetam monotherapy in Alzheimer patients with late-onset seizures: a prospective observational study.
Levetiracetam (LEV) monotherapy was investigated in 25 patients with advanced Alzheimer's disease (AD) and new-onset epileptic seizures in a prospective open-label study. At a daily dose of 1000-1500 mg, 72% were seizure-free for at least one year; 16% discontinued for untolerability; 8% were unresponsive; 4% were lost to follow-up. These results suggest the need for controlled studies to confirm if LEV can be a first-choice drug in AD.
Belcastro
V
V
Clinica Neurologica, Università degli Studi di Perugia, Ospedale S. Maria della Misericordia, Perugia, Italy.
Costa
C
C
Galletti
F
F
Pisani
F
F
Calabresi
P
P
Parnetti
L
L
D000368:Aged; D000369:Aged, 80 and over; D000544:Alzheimer Disease / Q000150:complications* / Q000188:drug therapy*; D005260:Female; D006801:Humans; D000077287:Levetiracetam; D008297:Male; D010889:Piracetam / Q000008:administration & dosage / Q000031:analogs & derivatives*; D011446:Prospective Studies; D012640:Seizures / Q000150:complications* / Q000188:drug therapy*
D000077287:Levetiracetam; D010889:Piracetam